Drugs / VEE IA/B V3526
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00109304 | Jul 2005 → Dec 2006 | Venezuelan equine encephalitis | DynPort Vaccine Company LLC, A GDIT Company | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VEE IA/B V3526 | “This study is being done to determine the safety and tolerability of a new investigational vaccine referred to as VEE IA/B V3526” NCT00109304 ↗ |
| Modality | Vaccine | “attenuated live-virus vaccine” NCT00109304 ↗ |
| Route | Subcutaneous | “single dose subcutaneous administration” NCT00109304 ↗ |